brentuximab vedotin
seagen,takeda
['congrat', 'brentuximab vedotin', 'hodgkin', 'lymphoma']
congratulations to , , &amp; the ahod1331 study team on defining a new standard for high risk #pediatric &amp; #adolescent #hodgkin #lymphoma - 3 yr efs of 92% w/ #brentuximab vedotin represents the best outcome for high risk hl to date. #cog #asco22 
Pediatric Oncologist @RoswellPark @OCH @Jacobs_Med_UB. Hodgkin Lymphoma, ALL. Mentoring next generation of physician researchers. Views are my own.